Batlevi CL et al. Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: Phase 1b results of Symphony-1. ASH 2022;Abstract 623.

Bödör et al. EZH2 gain of function mutations are not associated with more favorable prognosis in R/R follicular lymphoma: Prelim analysis of 908 patients. European School of Hematology (ESH) How to Diagnose and Treat Lymphoma Virtual Conference, November 6–8, 2020.

Horwitz SM et al. Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: Primary results of the phase 2 VALENTINE-PTCL01 study. ASH 2023;Abstract 302.

Leonard JP et al. A phase 1b/3 randomized, double-blind, 3-stage study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma. ASH 2020;Abstract 2052.

Morschhauser F et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:1433-42. Abstract